5/10
12:31 am
crbp
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Low
Report
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
5/9
08:00 am
crbp
Corbus Pharmaceuticals to Participate in the 2024 RBC Capital Markets Global Healthcare Conference
Low
Report
Corbus Pharmaceuticals to Participate in the 2024 RBC Capital Markets Global Healthcare Conference
5/8
12:39 pm
crbp
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) had its price target raised by analysts at Oppenheimer Holdings Inc. from $58.00 to $60.00. They now have an "outperform" rating on the stock.
Low
Report
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) had its price target raised by analysts at Oppenheimer Holdings Inc. from $58.00 to $60.00. They now have an "outperform" rating on the stock.
5/7
08:14 am
crbp
Corbus Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
Medium
Report
Corbus Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
5/7
08:00 am
crbp
Corbus Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
Medium
Report
Corbus Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
5/1
08:00 am
crbp
Corbus Pharmaceuticals to Participate in the BTIG Obesity Health Forum
Low
Report
Corbus Pharmaceuticals to Participate in the BTIG Obesity Health Forum
4/24
04:14 pm
crbp
Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO Annual Meeting [Yahoo! Finance]
Low
Report
Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO Annual Meeting [Yahoo! Finance]
4/24
04:05 pm
crbp
Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO Annual Meeting
Medium
Report
Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO Annual Meeting
4/19
02:44 pm
crbp
Neutral On Corbus Pharmaceuticals' Financials And Clinical Progress In Oncology [Seeking Alpha]
Low
Report
Neutral On Corbus Pharmaceuticals' Financials And Clinical Progress In Oncology [Seeking Alpha]
4/16
10:15 am
crbp
Here's What Could Help Corbus Pharmaceuticals (CRBP) Maintain Its Recent Price Strength [Yahoo! Finance]
Medium
Report
Here's What Could Help Corbus Pharmaceuticals (CRBP) Maintain Its Recent Price Strength [Yahoo! Finance]
4/2
09:41 am
crbp
Rachael Brake, PhD, Joins Zephyr AI as Chief Scientific Officer [Yahoo! Finance]
Low
Report
Rachael Brake, PhD, Joins Zephyr AI as Chief Scientific Officer [Yahoo! Finance]
4/2
08:24 am
crbp
Corbus Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC [Yahoo! Finance]
Low
Report
Corbus Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC [Yahoo! Finance]
4/2
08:00 am
crbp
Corbus Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC
Medium
Report
Corbus Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC
3/18
03:16 pm
crbp
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $58.00 price target on the stock, up previously from $51.00.
Low
Report
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $58.00 price target on the stock, up previously from $51.00.
3/15
11:05 am
crbp
What Makes Corbus Pharmaceuticals (CRBP) a Good Fit for 'Trend Investing' [Yahoo! Finance]
Medium
Report
What Makes Corbus Pharmaceuticals (CRBP) a Good Fit for 'Trend Investing' [Yahoo! Finance]
3/13
02:28 pm
crbp
BMO Hosts First Obesity Summit on Future of Obesity Care Market [Yahoo! Finance]
Low
Report
BMO Hosts First Obesity Summit on Future of Obesity Care Market [Yahoo! Finance]
3/12
08:17 am
crbp
Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update [Yahoo! Finance]
High
Report
Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update [Yahoo! Finance]
3/12
08:00 am
crbp
Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
High
Report
Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
3/6
08:12 am
crbp
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) was upgraded by analysts at Jefferies Financial Group Inc. from a "hold" rating to a "buy" rating. They now have a $46.00 price target on the stock, up previously from $4.00.
High
Report
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) was upgraded by analysts at Jefferies Financial Group Inc. from a "hold" rating to a "buy" rating. They now have a $46.00 price target on the stock, up previously from $4.00.
3/6
08:11 am
crbp
Corbus Pharmaceuticals to Participate in the BMO Capital Markets Inaugural Obesity Summit [Yahoo! Finance]
Medium
Report
Corbus Pharmaceuticals to Participate in the BMO Capital Markets Inaugural Obesity Summit [Yahoo! Finance]
3/6
08:00 am
crbp
Corbus Pharmaceuticals to Participate in the BMO Capital Markets Inaugural Obesity Summit
High
Report
Corbus Pharmaceuticals to Participate in the BMO Capital Markets Inaugural Obesity Summit
2/28
11:06 pm
crbp
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
High
Report
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
2/28
08:00 am
crbp
Corbus Pharmaceuticals Appoints Dr. Dominic Smethurst as Chief Medical Officer
Medium
Report
Corbus Pharmaceuticals Appoints Dr. Dominic Smethurst as Chief Medical Officer
2/12
10:05 pm
crbp
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Medium
Report
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.